不同剂量泰嘉在心肌梗死PCI术后患者中的疗效及安全性比较

Efficacy and safety of different doses of Talcom in patients one year later after underwent percutaneous coronary intervention for myocardial infarction

目的观察经皮冠状动脉介入(PCI)手术1年后患者服用不同剂量国产氯吡格雷(商品名:泰嘉)的疗效及安全性。方法 120例急性心肌梗死PCI术后患者,阿司匹林+波立维双抗满1年后,随机分为A组(阿司匹林100mg 1次/d、波立维75mg 1次/d)、B组(阿司匹林100mg 1次/d、泰嘉75mg,1次/d)、C组(阿司匹林100mg 1次/d、泰嘉50mg 1次/d)、D组(阿司匹林100mg 1次/d、泰嘉25mg 1次/d),随访1年,比较各组不良心血管事件及药物不良反应情况。结果 D组患者累计MACE事件较A组明显上升,差异有统计学意义(χ~2=6.149,P=0.014),B、C两组与A组比较,差异均无明显统计学意义(均P>0.05)。各组出血事件及血小板减少率、胃肠道反应均无明显统计学差异(均P>0.05),且各组均未出现致死性出血事件。结论泰嘉预防心肌梗死PCI术1年后心血管事件在疗效及安全性与波立维相当,最小剂量至少50mg/d。

] Objective To investigate the efficacy and safety of different doses of Talcom in patients one year laterafter underwent percutaneous coronary stent implantation for acute myocardial infarction （AMI）. Methods 120 patientsunderwent PCI for AMI were treated with aspirin plus Clopidogrel for 1 year and then randomly divided into groupA（aspirin ＋ Clopidogrel）, group B （aspirin ＋ Talcom 75mg）, group C（ aspirin ＋ Talcom 50mg） and group D（aspirin ＋ Talcom25mg）. Adverse cardiovascular events and drug reactions were compared between each group during follow-up oneyear. Results Adverse cardiovascular events were significantly higher in groupD than in group A（P〈0.05） but was nosignificant difference between group B, group C and group A. There was no significant difference of bleeding events, theincidence of thrombocytopenia and gastrointestinal reaction between different groups. Conclusion The efficacy andsafety of Talcom with minimum dose at least 50mg every day in prevention of cardiovascular events one year later after AMIPCI are equal to that of Clopidogrel.[